Table 3. Genetic and allelic frequencies of SNPs studied in OA patients and controls.
| Gene (SNP rs ID) | OA N (%) | Controls N (%) | OR* | (95% CI) | p | HWE in controls |
|---|---|---|---|---|---|---|
| VEGFA (rs3025039) | ||||||
| CC | 31 (38.7) | 57 (47.9) | 1.00 | Reference | ||
| CT | 37 (46.2) | 44 (37.0) | 1.48 | (0.76 – 2.88) | 0.25 | 0.061 |
| TT | 12 (15.0) | 18 (15.1) | 1.23 | (0.50 – 3.03) | 0.64 | |
| T | 61 (38.1) | 79 (33.6) | 1.20 | (0.77 – 1.88) | 0.41 | |
| VEGFA (rs699947) | ||||||
| CC | 39 (48.1) | 57 (50.0) | 1.00 | Reference | 0.063 | |
| CA | 34 (42.0) | 41 (36.0) | 1.03 | (0.50 – 2.12) | 0.93 | |
| AA | 8 (9.90) | 16 (14.0) | 0.54 | (0.17 – 11.7) | 0.28 | |
| A | 50 (30.9) | 73 (32.0) | 0.81 | (0.49 – 1.35) | 0.43 | |
| HIF1AN (rs11292) | ||||||
| AA | 61 (81.3) | 51 (58.6) | 1.00 | Reference | 0.011 | |
| AG | 0 (0.00) | 25 (28.7) | - | - | - | |
| GG | 14 (18.7) | 11 (12.6) | 0.68 | (0.25 – 1.78) | 0.43 | |
| G | 28 (18.7) | 47 (27.0) | 0.58 | (0.30 – 1.09) | 0.09 | |
| COL3A1 (rs1800255) | ||||||
| GG | 35 (41.7) | 30 (40.5) | 1.00 | Reference | 0.102 | |
| GA | 42 (50.0) | 39 (52.7) | 1.36 | (0.63 – 2.92) | 0.42 | |
| AA | 7 (8.33) | 5 (6.76) | 2.20 | (0.41 – 11.7) | 0.35 | |
| G | 112 (66.7) | 99 (66.9) | 1.00 | Reference | ||
| A | 56 (33.3) | 49 (33.1) | 1.29 | (0.76 – 2.20) | 0.33 | |
| EGF (rs4444903) | ||||||
| GG | 23 (28.0) | 31 (27.9) | 1.00 | Reference | 0.890 | |
| GA | 41 (50.0) | 56 (50.5) | 1.04 | (0.48 – 2.27) | 0.90 | |
| AA | 18 (22.0) | 24 (21.6) | 1.51 | (0.58 – 3.91) | 0.39 | |
| A | 77 (47.0) | 104 (46.8) | 1.20 | (0.75 – 1.92) | 0.42 | |
| MMP3 (rs679620) | ||||||
| CC | 39 (48.7) | 41 (51.9) | 1.00 | Reference | 0.073 | |
| CT | 30 (37.5) | 27 (34.2) | 2.17 | (0.93 – 5.08) | 0.07 | |
| TT | 11 (13.8) | 11 (13.9) | 0.88 | (0.32 – 2.41) | 0.81 | |
| T | 52 (32.5) | 49 (31.0) | 1.09 | (0.64 – 1.87) | 0.73 | |
| MMP13 (rs2252070) | ||||||
| TT | 38 (44.7) | 46 (48.9) | 1.00 | Reference | 0.602 | |
| TC | 41 (48.2) | 41 (43.6) | 1.18 | (0.62 – 2.26) | 0.60 | |
| CC | 6 (7.10) | 7 (7.50) | 1.09 | (0.32 – 3.71) | 0.89 | |
| C | 53 (31.2) | 55 (29.3) | 1.09 | (0.68 – 1.76) | 0.70 | |
| NOS2 (rs2297518) | ||||||
| GG | 65 (81.2) | 66 (80.5) | 1.00 | Reference | 0.887 | |
| GA | 14 (17.5) | 15 (18.3) | 0.86 | (0.37 – 2.03) | 0.75 | |
| AA | 1 (1.25) | 1 (1.22) | 1.51 | (0.08 – 26.0) | 0.78 | |
| A | 16 (10.0) | 17 (10.4) | 0.94 | (0.44 – 2.01) | 0.89 | |
| NOS3 (rs2070744) | ||||||
| TT | 58 (66.7) | 53 (63.1) | 1.00 | Reference | 0.092 | |
| TC | 23 (26.4) | 24 (28.6) | 0.89 | (0.42 – 1.86) | 0.77 | |
| CC | 6 (6.90) | 7 (8.33) | 0.64 | (0.19 – 2.17) | 0.48 | |
| C | 35 (20.1) | 38 (22.6) | 0.80 | (0.46 – 1.40) | 0.45 |
*
The multi-variable model was adjusted for age (continuous data), gender (male, female), BMI (continous data) and admixture; OA, osteoarthritis patients; OR, Odds ratio; CI, confidence interval. HWE, Hardy-Weinberg equilibrium; if p<0.05, it is not consistent with HWE. Significant p-values are in bold.